Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Peter Schmid, MD, PhD: Update on IMpassion130: Use of Doublet to Treat Triple-Negative Breast Cancer

Posted: Monday, June 17, 2019

Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discusses the clinical impact of new data confirming the clinically meaningful overall survival benefit of atezolizumab plus nab-paclitaxel in previously untreated PD-L1–positive metastatic triple-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.